CERE - Cerevel Therapeutics GAAP EPS of -$0.59 beats by $0.05
- Cerevel Therapeutics press release ( NASDAQ: CERE ): Q4 GAAP EPS of -$0.59 beats by $0.05 .
- Cash, cash equivalents and marketable securities as of December 31, 2022, were $950.2 million, compared to $618.0 million as of December 31, 2021.
For further details see:
Cerevel Therapeutics GAAP EPS of -$0.59 beats by $0.05